Effects of combined treatment using umbilical cord blood mesenchymal stem cell transplantation and paclitaxel on proliferation, apoptosis, and invasion of A2780 ovarian cancer cells

doi:10.3969/j.issn.2095-4344.2016.20.006

Abstract

Abstract:

BACKGROUND: An intensive study on ovarian cancer A2780 cells contributes to modify treatment strategies targeting ovarian cancer stem cells and enhance survival rate of ovarian cancer patients.
OBJECTIVE: To investigate the effects of umbilical cord blood mesenchymal stem cells (UC-MSCs) transplantation combined with paclitaxel on proliferation, apoptosis, and invasion of A2780 human ovarian cancer cells in vitro.
METHODS: A2780 human ovarian cancer cells were assigned into three groups: blank control group (routine cell culture), UC-MSCs group (addition of suspension containing 1×106 UC-MSCs) and combined treatment group (combined addition of suspension containing 1×106 UC-MSCs and 250 μL of 1 μmol/L paclitaxel solution). CD133+ antigen expression, proliferation, apoptosis, and invasion were determined by immunofluorescent staining, flow cytometry, TUNEL staining, and Transwell chamber invasion assay, respectively.
RESULTS AND CONCLUSON: CD133+ antigen expression in the UC-MSCs group and combined treatment group was significantly decreased compared with the blank control group (P < 0.05). Proliferation and invasion abilities were significantly decreased, while apoptosis cell number was significantly increased in the combined treatment group compared with the other two groups (P < 0.05). These findings indicate that the combined treatment of UC-MSCs transplantation and paclitaxel can inhibit proliferation and invasion and promote apoptosis of A2780 human ovarian cancer cells.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

Key words: Fetal Blood, Mesenchymal Stem Cells, Paclitaxel, Ovarian Neoplasms

CLC Number:

R318

Chen Feng-zhen, Yin Li-rong. Effects of combined treatment using umbilical cord blood mesenchymal stem cell transplantation and paclitaxel on proliferation, apoptosis, and invasion of A2780 ovarian cancer cells[J]. Chinese Journal of Tissue Engineering Research, 2016, 20(20): 2927-2932.

Figures/Tables 5

References

[1] 樊蓓,李红霞,吴玉梅,等.紫杉醇诱导的卵巢癌耐药细胞株的生物学特性及其保存[J].肿瘤防治研究,2015,42(4):334-339.

[2] Kim YW, Kim EY, Jeon D, et al. Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. Drug Des Devel Ther. 2014;8:293-314.

[3] 刘太圣.白蛋白结合型紫杉醇与紫杉醇脂质体治疗复发性卵巢癌近期疗效及对Twist蛋白和血管内皮生长因子表达的影响[J].中国医学前沿杂志:电子版,2015,7(6):168-171.

[4] 张玥,黄春梅,邹于征,等.白细胞介素-2联合紫杉醇及卡铂治疗晚期卵巢癌疗效观察[J].临床医学,2014,34(1):1-3.

[5] Wang X, Wang C, Sun YT, et al. Taxol produced from endophytic fungi induces apoptosis in human breast, cervical and ovarian cancer cells.Asian Pac J Cancer Prev. 2015;16(1):125-131.

[6] 于俊丽. 紫杉醇联合卡铂不同给药途径治疗卵巢癌52例疗效分析[J].中国现代药物应用,2015,9(3):134-135.

[7] Suh YA, Jo SY, Lee HY, et al. Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells. Int J Oncol. 2015;46(3):1405-1411.

[8] 王欢,刘富萍.VEGF-C在宫颈癌中的研究现状与展望[J].四川解剖学杂志,2011,19(3):30-33.

[9] 傅君,叶大风,傅云峰,等.紫杉醇耐药卵巢癌细胞亚株的蛋白组学研究 [J].中国临床药理学与治疗学,2015,20(5): 525-530.

[10] Armstrong EH, Goswami D, Griffin PR, et al. Structural basis for ligand regulation of the fatty acid-binding protein 5, peroxisome proliferator-activated receptor β/δ (FABP5-PPARβ/δ) signaling pathway. J Biol Chem. 2014;289(21):14941-14954.

[11] 王伟,殷红梅.宫颈癌组织中Fhit、survivin和Bcl-2的表达变化及意义[J].山东医药,2011,51(30):42-43.

[12] Li W, Wan L, Zhai LY, et al. Effects of SC-560 in combination with cisplatin or taxol on angiogenesis in human ovarian cancer xenografts.Int J Mol Sci. 2014; 15(10):19265-19280.

[13] 陈燕,林莺莺,陈岩松,等.原发性宫颈癌早期诊断中甲胎蛋白异质体检测的意义[J].福建医药杂志,2012,34(1):3-6.

[14] Gu TT, Liu SY, Zheng PS. Cytoplasmic NANOG-positive stromal cells promote human cervical cancer progression. Am J Pathol. 2012;181(2):652-661.

[15] 李碧慧.紫杉醇联合卡铂化疗应用于卵巢癌中的疗效探析[J].医学信息,2015,28(23):368-368.

[16] Gu W, Yeo E, McMillan N, et al. Silencing oncogene expression in cervical cancer stem-like cells inhibits their cell growth and self-renewal ability. Cancer Gene Ther. 2011;18(12):897-905.

[17] 黄玲.低剂量奥沙利铂联合紫杉醇诱导人卵巢癌细胞A2780凋亡的内质网应激机制研究[J].海南医学院学报, 2015,21(3):299-302.

[18] 卢雪琳,杨陈,梁晓秋,等.OSTP增强紫杉醇诱导卵巢癌A2780细胞凋亡的作用[J].医学研究杂志,2014,43(4): 42-46.

[19] Zhang SL, Wang YS, Zhou T, et al. Isolation and characterization of cancer stem cells from cervical cancer HeLa cells. Cytotechnology. 2012;64(4):477-484.

[20] 刘晨,安晓霞,张凡,等.肿瘤干细胞相关基因ABCB1、ABCG2表达与宫颈上皮恶变及发展关系的研究[J].现代妇产科进展,2012,24(4):294-297.

[21] 周敏,张靖,赵西侠,等.热疗联合紫杉醇对卵巢癌 A2780细胞增殖、侵袭及AKT磷酸化的影响[J].现代肿瘤医学, 2015,23(20):2904-2907.

[22] 张松灵,张立红,钟艳平,等.人宫颈癌组织中CKl7和P63蛋白的表达及意义[J].吉林大学学报:医学版,2009,35(5): 914-917.

[23] Choijamts B, Jimi S, Kondo T, et al. CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor). Stem Cells. 2011;29(10):1485-1495.

[24] 石芳,徐战战,左泽华,等.siRNA抑制eIF4E基因的表达对卵巢癌A2780细胞生物学行为的影响[J].武汉大学学报:医学版,2015,36(2):248-253.

[25] Götte M, Greve B, Kelsch R, et al. The adult stem cell marker Musashi-1 modulates endometrial carcinoma cell cycle progression and apoptosis via Notch-1 and p21WAF1/CIP1. Int J Cancer. 2011;129(8):2042-2049.

[26] 吴翌楠,王苏立,王迎春,等.DHA 逆转卵巢癌细胞A2780/T紫杉醇耐药的机制研究[J]东南大学学报:医学版,2015,34(5):689-695.

[27] Liu Q, Sui R, Li R, et al. Biological characteristics of Taxol?resistant ovarian cancer cells and reversal of Taxol resistance by adenovirus expressing p53. Mol Med Rep. 2015;11(2):1292-1297.

[28] Shishido Y, Ueno S, Yamazaki R, et al. ABCG2 inhibitor YHO-13351 sensitizes cancer stem/initiating-like side population cells to irinotecan. Anticancer Res. 2013;33(4):1379-1386.

[29] 马晓丽. 紫杉醇脂质体联合顺铂静脉化疗卵巢癌的护理[J].医学信息,2015,28(z1):73.

[30] Sun NK, Huang SL, Chang PY, et al. Transcriptomic profiling of taxol-resistant ovarian cancer cells identifies FKBP5 and the androgen receptor as critical markers of chemotherapeutic response. Oncotarget. 2014;5(23):11939-11956.